Display options
Cite
Tchounwou PB, Dasari S, Noubissi FK, et al. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol. 2021;13:303-328doi: 10.2147/JEP.S267383.
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021). Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. Journal of experimental pharmacology, 13303-328. https://doi.org/10.2147/JEP.S267383
Tchounwou, Paul B, et al. "Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy." Journal of experimental pharmacology vol. 13 (2021): 303-328. doi: https://doi.org/10.2147/JEP.S267383
Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol. 2021 Mar 18;13:303-328. doi: 10.2147/JEP.S267383. eCollection 2021. PMID: 33776489; PMCID: PMC7987268.
Copy Download .nbib Format: NLM
Share it on

J Exp Pharmacol. 2021 Mar 18;13:303-328. doi: 10.2147/JEP.S267383. eCollection 2021.

Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.

Journal of experimental pharmacology

Paul B Tchounwou, Shaloam Dasari, Felicite K Noubissi, Paresh Ray, Sanjay Kumar

Affiliations

  1. Cellomics and Toxicogenomics Research Laboratory, NIH-RCMI Center for Health Disparities Research, Jackson State University, Jackson, MS, USA.
  2. Department of Chemistry and Biochemistry, College of Science, Engineering and Technology, Jackson State University, Jackson, MS, USA.
  3. Department of Life Sciences, School of Earth, Biological, and Environmental Sciences, Central University of South Bihar, Gaya, India.

PMID: 33776489 PMCID: PMC7987268 DOI: 10.2147/JEP.S267383

Abstract

Cisplatin and other platinum-based chemotherapeutic drugs have been used extensively for the treatment of human cancers such as bladder, blood, breast, cervical, esophageal, head and neck, lung, ovarian, testicular cancers, and sarcoma. Cisplatin is commonly administered intravenously as a first-line chemotherapy for patients suffering from various malignancies. Upon absorption into the cancer cell, cisplatin interacts with cellular macromolecules and exerts its cytotoxic effects through a series of biochemical mechanisms by binding to Deoxyribonucleic acid (DNA) and forming intra-strand DNA adducts leading to the inhibition of DNA synthesis and cell growth. Its primary molecular mechanism of action has been associated with the induction of both intrinsic and extrinsic pathways of apoptosis resulting from the production of reactive oxygen species through lipid peroxidation, activation of various signal transduction pathways, induction of p53 signaling and cell cycle arrest, upregulation of pro-apoptotic genes/proteins, and down-regulation of proto-oncogenes and anti-apoptotic genes/proteins. Despite great clinical outcomes, many studies have reported substantial side effects associated with cisplatin monotherapy, while others have shown substantial drug resistance in some cancer patients. Hence, new formulations and several combinational therapies with other drugs have been tested for the purpose of improving the clinical utility of cisplatin. Therefore, this review provides a comprehensive understanding of its molecular mechanisms of action in cancer therapy and discusses the therapeutic approaches to overcome cisplatin resistance and side effects.

© 2021 Tchounwou et al.

Keywords: cancer treatment; cisplatin; combination therapy; molecular mechanisms of action

Conflict of interest statement

All authors have declared that they do not have any competing and/or financial interests for this work.

References

  1. J Biomed Mater Res B Appl Biomater. 2019 Nov;107(8):2658-2663 - PubMed
  2. ACS Nano. 2019 Nov 26;13(11):13445-13455 - PubMed
  3. Mol Pharmacol. 2008 Feb;73(2):461-8 - PubMed
  4. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302 - PubMed
  5. Angew Chem Int Ed Engl. 2017 Oct 23;56(44):13838-13841 - PubMed
  6. Cancer. 2001 Jun 15;91(12):2288-93 - PubMed
  7. Int J Cancer Res Mol Mech. 2015 Oct;1(3): - PubMed
  8. ACS Appl Mater Interfaces. 2017 Mar 22;9(11):9426-9436 - PubMed
  9. Toxicol Sci. 2006 Feb;89(2):515-23 - PubMed
  10. Am J Physiol. 1996 Apr;270(4 Pt 2):F700-8 - PubMed
  11. J Clin Oncol. 2010 Jul 10;28(20):3299-306 - PubMed
  12. DNA Repair (Amst). 2002 Dec 5;1(12):1003-16 - PubMed
  13. Oncotarget. 2014 Jun 15;5(11):3455-71 - PubMed
  14. Anticancer Agents Med Chem. 2007 Jan;7(1):3-18 - PubMed
  15. PLoS One. 2011;6(9):e24671 - PubMed
  16. J Biol Chem. 2000 Nov 17;275(46):35778-85 - PubMed
  17. Nat Nanotechnol. 2007 Dec;2(12):751-60 - PubMed
  18. J Cell Mol Med. 2016 Nov;20(11):2013-2019 - PubMed
  19. Curr Med Chem. 2009;16(25):3267-85 - PubMed
  20. J Cell Physiol. 2017 Dec;232(12):3433-3443 - PubMed
  21. Mol Pharmacol. 2003 Aug;64(2):466-73 - PubMed
  22. Nature. 1995 Aug 17;376(6541):599-602 - PubMed
  23. J Am Chem Soc. 2010 Dec 8;132(48):17130-8 - PubMed
  24. World J Gastroenterol. 2009 Apr 14;15(14):1779-81 - PubMed
  25. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265-9 - PubMed
  26. World J Urol. 2007 Apr;25(2):199-205 - PubMed
  27. J Clin Oncol. 2005 Aug 1;23(22):4999-5006 - PubMed
  28. J Nucleic Acids. 2010 Aug 08;2010: - PubMed
  29. Cancer. 1994 Apr 15;73(8):2013-26 - PubMed
  30. Bioeng Transl Med. 2016 Jun 03;1(1):10-29 - PubMed
  31. Hum Cell. 2001 Dec;14(4):305-15 - PubMed
  32. J Clin Oncol. 2006 Jan 1;24(1):36-44 - PubMed
  33. Gynecol Oncol. 1993 Aug;50(2):147-58 - PubMed
  34. Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):13943-13951 - PubMed
  35. Int J Cancer. 2005 Dec 10;117(5):755-63 - PubMed
  36. Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218 - PubMed
  37. Cancer Res. 2004 Jan 15;64(2):517-22 - PubMed
  38. J Funct Foods. 2018 Jan;40:573-581 - PubMed
  39. J Clin Oncol. 1999 Mar;17(3):968-75 - PubMed
  40. Mol Endocrinol. 2003 May;17(5):777-91 - PubMed
  41. J Biol Chem. 2002 Nov 8;277(45):43377-88 - PubMed
  42. Cancer Lett. 2020 Mar 1;472:59-69 - PubMed
  43. Mol Biol Cell. 2002 Feb;13(2):393-401 - PubMed
  44. Int J Cancer. 2004 Jun 20;110(3):352-61 - PubMed
  45. J Urol. 1991 Nov;146(5):1284-7 - PubMed
  46. Eur J Cancer. 2010 Mar;46(5):885-91 - PubMed
  47. Pharmacol Ther. 1993 Sep;59(3):257-80 - PubMed
  48. Acta Biomater. 2019 Jan 15;84:367-377 - PubMed
  49. Int J Cancer. 2008 Jan 15;122(2):289-97 - PubMed
  50. Mol Cell Biol. 2008 Aug;28(16):5082-92 - PubMed
  51. Cancer Res. 1997 Dec 15;57(24):5475-9 - PubMed
  52. Nat Rev Clin Oncol. 2020 Jul;17(7):395-417 - PubMed
  53. Cancer Res. 1995 Sep 1;55(17):3752-6 - PubMed
  54. World J Gastroenterol. 2014 Aug 7;20(29):9744-58 - PubMed
  55. Int J Clin Exp Med. 2014 Sep 15;7(9):2530-40 - PubMed
  56. Biol Trace Elem Res. 2020 Sep;197(1):52-62 - PubMed
  57. Curr Cancer Drug Targets. 2009 May;9(3):354-65 - PubMed
  58. Int J Mol Sci. 2020 Jun 03;21(11): - PubMed
  59. Theranostics. 2019 Jan 30;9(4):1096-1114 - PubMed
  60. ACS Nano. 2011 Dec 27;5(12):9480-93 - PubMed
  61. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17939-44 - PubMed
  62. Anticancer Res. 2004 Jul-Aug;24(4):2193-200 - PubMed
  63. Cancer Lett. 1987 Aug;36(2):197-201 - PubMed
  64. Head Neck. 2018 Jan;40(1):70-78 - PubMed
  65. Oncotarget. 2015 Dec 1;6(38):40734-46 - PubMed
  66. Nature. 1995 Aug 31;376(6543):785-8 - PubMed
  67. Cell. 2002 Jan 25;108(2):171-82 - PubMed
  68. Cancer Lett. 2019 Feb 1;442:396-408 - PubMed
  69. Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37 - PubMed
  70. Mol Cell Biol. 2001 Oct;21(20):6913-26 - PubMed
  71. Anticancer Drugs. 2008 Oct;19(9):927-9 - PubMed
  72. Am J Med. 2000 Apr 1;108(5):403-15 - PubMed
  73. Cancer Metastasis Rev. 2007 Mar;26(1):71-83 - PubMed
  74. Cell Physiol Biochem. 2018;47(1):279-292 - PubMed
  75. Arch Physiol Biochem. 2019 Sep 28;:1-9 - PubMed
  76. Cancer Res. 2009 Dec 1;69(23):8910-7 - PubMed
  77. ACS Appl Mater Interfaces. 2020 Sep 30;12(39):43408-43421 - PubMed
  78. J Comput Chem. 2005 Jul 15;26(9):907-14 - PubMed
  79. Antioxid Redox Signal. 2008 Dec;10(12):2023-33 - PubMed
  80. J Clin Oncol. 2015 Dec 10;33(35):4219-26 - PubMed
  81. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 - PubMed
  82. J Lab Clin Med. 1998 Jun;131(6):518-26 - PubMed
  83. Adv Sci (Weinh). 2018 Jan 08;5(4):1700513 - PubMed
  84. Science. 2002 Dec 6;298(5600):1911-2 - PubMed
  85. Life Sci. 2020 Mar 1;244:117329 - PubMed
  86. Cell Oncol (Dordr). 2018 Jun;41(3):319-328 - PubMed
  87. Bioorg Med Chem Lett. 2017 Dec 15;27(24):5400-5403 - PubMed
  88. Tumour Biol. 2015 May;36(5):3591-9 - PubMed
  89. J Exp Med. 2005 Jan 17;201(2):279-89 - PubMed
  90. J Biol Chem. 2001 Jul 27;276(30):28546-53 - PubMed
  91. Neurosci Lett. 2002 Apr 5;322(2):103-6 - PubMed
  92. Cell Signal. 2021 Feb;78:109871 - PubMed
  93. J Clin Oncol. 2007 Jul 1;25(19):2804-10 - PubMed
  94. Oncol Lett. 2016 Apr;11(4):2411-2419 - PubMed
  95. Food Funct. 2012 Feb;3(2):164-9 - PubMed
  96. J Nephropathol. 2017 Jul;6(3):163-167 - PubMed
  97. Toxins (Basel). 2010 Nov;2(11):2490-518 - PubMed
  98. Urol Res. 1999 Jun;27(3):157-63 - PubMed
  99. J Bacteriol. 1973 Dec;116(3):1247-52 - PubMed
  100. Biomed Pharmacother. 2020 Jul;127:110234 - PubMed
  101. Cell Death Dis. 2019 Dec 9;10(12):936 - PubMed
  102. Materials (Basel). 2017 Mar 14;10(3): - PubMed
  103. Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):17-22 - PubMed
  104. Nat Rev Cancer. 2002 Jan;2(1):48-58 - PubMed
  105. Drug Metab Dispos. 2003 Jul;31(7):916-23 - PubMed
  106. J BUON. 2018 Sep-Oct;23(5):1402-1406 - PubMed
  107. Oncol Lett. 2017 Apr;13(4):2805-2810 - PubMed
  108. Trends Cell Biol. 2013 Dec;23(12):620-33 - PubMed
  109. Clin Cancer Res. 2017 Nov 1;23(21):6592-6601 - PubMed
  110. Biomater Sci. 2015 Jan;3(1):182-91 - PubMed
  111. Nanomaterials (Basel). 2015 Dec 16;5(4):2302-2316 - PubMed
  112. Cell Biol Int. 2016 Oct;40(10):1094-106 - PubMed
  113. Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 - PubMed
  114. Mol Aspects Med. 2008 Dec;29(6):433-52 - PubMed
  115. Nephrol Dial Transplant. 1997 Dec;12(12):2478-80 - PubMed
  116. Sci Rep. 2015 Jul 23;5:12291 - PubMed
  117. Pharmacol Res. 2019 May;143:178-185 - PubMed
  118. Nanomedicine (Lond). 2018 Nov;13(21):2729-2758 - PubMed
  119. J Biol Chem. 2003 Mar 14;278(11):9100-6 - PubMed
  120. Int J Cancer. 1997 Mar 4;70(5):551-5 - PubMed
  121. Anticancer Res. 2011 Dec;31(12):4501-5 - PubMed
  122. J Clin Oncol. 2005 May 20;23(15):3562-7 - PubMed
  123. Immunity. 2014 May 15;40(5):772-784 - PubMed
  124. Cancer Cell. 2004 Aug;6(2):139-50 - PubMed
  125. Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745 - PubMed
  126. J Clin Oncol. 2003 Jan 1;21(1):54-9 - PubMed
  127. Cancer J. 2000 Sep-Oct;6(5):316-23 - PubMed
  128. Mol Pharmacol. 2008 Sep;74(3):697-704 - PubMed
  129. Cancer Chemother Pharmacol. 2018 Mar;81(3):539-548 - PubMed
  130. Oncogene. 1999 Apr 8;18(14):2335-41 - PubMed
  131. J Biol Chem. 1996 Sep 20;271(38):23512-9 - PubMed
  132. J Biol Chem. 1993 Sep 25;268(27):20116-25 - PubMed
  133. Cancer Res. 1995 Feb 1;55(3):474-7 - PubMed
  134. Clin Cancer Res. 2004 Jul 15;10(14):4661-9 - PubMed
  135. Nanomaterials (Basel). 2020 Mar 11;10(3): - PubMed
  136. Cancer Res. 1991 Jun 15;51(12):3237-42 - PubMed
  137. Biochem Biophys Res Commun. 2005 Sep 9;334(4):1068-73 - PubMed
  138. Cancer Lett. 2008 Feb 18;260(1-2):96-108 - PubMed
  139. Indian J Exp Biol. 1996 Oct;34(10):995-8 - PubMed
  140. Mol Cell Biochem. 2012 May;364(1-2):11-8 - PubMed
  141. ACS Nano. 2013 Nov 26;7(11):9896-904 - PubMed
  142. Toxicol In Vitro. 2012 Apr;26(3):435-44 - PubMed
  143. Ageing Res Rev. 2013 Jan;12(1):376-90 - PubMed
  144. Carbohydr Polym. 2019 Dec 1;225:115206 - PubMed
  145. Oncogene. 2008 Jul 10;27(30):4221-32 - PubMed
  146. Int J Pharm. 2002 Mar 20;235(1-2):179-92 - PubMed
  147. J Biol Chem. 1997 May 30;272(22):14041-4 - PubMed
  148. Hear Res. 2013 May;299:37-45 - PubMed
  149. Cell Death Differ. 2003 Apr;10(4):431-42 - PubMed
  150. Asian J Androl. 2006 Sep;8(5):607-12 - PubMed
  151. Biol Cell. 2008 Nov;100(11):617-31 - PubMed
  152. Dalton Trans. 2010 Feb 7;39(5):1295-301 - PubMed
  153. Oncol Rep. 2004 Feb;11(2):493-9 - PubMed
  154. Oncol Rep. 2015 Sep;34(3):1460-8 - PubMed
  155. J Cancer Sci Ther. 2019;11(4): - PubMed
  156. Oncology. 1997;54 Suppl 1:12-8 - PubMed
  157. Asian Pac J Cancer Prev. 2019 Jan 25;20(1):303-309 - PubMed
  158. J Am Chem Soc. 2003 Nov 19;125(46):14082-92 - PubMed
  159. Int J Cancer. 1993 Oct 21;55(4):678-84 - PubMed
  160. J Biol Chem. 1999 Oct 29;274(44):31648-54 - PubMed
  161. Science. 1988 Sep 30;241(4874):1813-5 - PubMed
  162. PLoS One. 2015 Aug 06;10(8):e0135083 - PubMed
  163. Am J Physiol Renal Physiol. 2004 Feb;286(2):F378-84 - PubMed
  164. Curr Med Chem. 2008;15(26):2702-17 - PubMed
  165. Cell. 1995 Jan 27;80(2):179-85 - PubMed
  166. FEBS J. 2015 May;282(10):1841-57 - PubMed
  167. Sci Rep. 2017 Apr 05;7:45983 - PubMed
  168. Nature. 2001 Mar 1;410(6824):37-40 - PubMed
  169. Biochemistry. 1985 Jan 29;24(3):707-13 - PubMed
  170. Cancer Res. 2003 Jun 15;63(12):3418-24 - PubMed
  171. Drug Deliv. 2019 Dec;26(1):765-772 - PubMed
  172. Phytomedicine. 2019 May;58:152805 - PubMed
  173. Molecules. 2018 Sep 06;23(9): - PubMed
  174. J Cell Biochem. 2020 Feb;121(2):1575-1585 - PubMed
  175. ACS Appl Mater Interfaces. 2018 Oct 3;10(39):33060-33069 - PubMed
  176. Nature. 1965 Feb 13;205:698-9 - PubMed
  177. N Engl J Med. 2009 Oct 22;361(17):1662-70 - PubMed
  178. Int J Nanomedicine. 2019 May 28;14:3753-3771 - PubMed
  179. Oncology. 2000 Nov;59(4):291-5 - PubMed
  180. Am J Pathol. 2012 Feb;180(2):517-25 - PubMed
  181. R Soc Open Sci. 2016 Sep 14;3(9):160287 - PubMed
  182. ACS Appl Mater Interfaces. 2014 Mar 26;6(6):4382-93 - PubMed
  183. Cancer Res. 2004 Apr 1;64(7):2343-6 - PubMed
  184. Gynecol Oncol. 2008 Oct;111(1):106-10 - PubMed
  185. J Clin Oncol. 1996 Mar;14(3):814-20 - PubMed
  186. J Cancer. 2010 Jul 15;1:101-7 - PubMed
  187. Chem Rev. 1999 Sep 8;99(9):2467-98 - PubMed
  188. Anticancer Res. 2005 Jul-Aug;25(4):3031-9 - PubMed
  189. Anticancer Res. 2019 Apr;39(4):1711-1718 - PubMed
  190. Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 - PubMed
  191. J Clin Oncol. 1999 Jan;17(1):319-23 - PubMed
  192. EMBO J. 2009 Feb 18;28(4):383-93 - PubMed
  193. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4247-52 - PubMed
  194. Cancer Res. 1993 Jul 15;53(14):3237-40 - PubMed
  195. J Natl Cancer Inst. 1993 May 19;85(10):794-800 - PubMed
  196. Ann Med. 2014 Sep;46(6):372-83 - PubMed
  197. Cancer Res Treat. 2017 Apr;49(2):416-422 - PubMed
  198. Eur J Pharmacol. 2011 Jan 10;650(1):335-41 - PubMed
  199. Am J Med Sci. 2007 Aug;334(2):115-24 - PubMed
  200. Clin Cancer Res. 2006 Oct 1;12(19):5817-25 - PubMed
  201. Oncol Rep. 2019 Nov;42(5):2087-2096 - PubMed
  202. Anticancer Drugs. 1998 Mar;9(3):191-201 - PubMed
  203. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84 - PubMed
  204. J Med Chem. 2001 Feb 1;44(3):472-4 - PubMed
  205. Theranostics. 2016 Jan 01;6(1):142-54 - PubMed
  206. Mutat Res. 2004 Dec 12;564(2):115-28 - PubMed
  207. Int J Cardiol. 2014 Jul 15;175(1):201-2 - PubMed
  208. Int J Mol Med. 2020 Apr;45(4):1213-1224 - PubMed
  209. Redox Biol. 2013 Jan 18;1:45-9 - PubMed
  210. J Biol Chem. 1994 Jan 14;269(2):787-90 - PubMed
  211. Biochem Biophys Res Commun. 2010 Apr 9;394(3):600-5 - PubMed
  212. J Clin Oncol. 1990 Sep;8(9):1585-90 - PubMed
  213. Kidney Int. 2008 Sep;74(5):631-40 - PubMed
  214. J Biol Chem. 2000 Dec 22;275(51):40400-6 - PubMed
  215. J Control Release. 2015 Oct 10;215:82-90 - PubMed
  216. Mol Pharmacol. 2001 Apr;59(4):657-63 - PubMed
  217. Invest New Drugs. 2004 Apr;22(2):185-92 - PubMed
  218. Hum Genomics. 2004 Nov;1(6):460-4 - PubMed
  219. Drugs. 1997 Sep;54(3):447-72 - PubMed
  220. Curr Med Chem Anticancer Agents. 2005 May;5(3):251-65 - PubMed
  221. Mol Cell Biol. 1999 Aug;19(8):5308-15 - PubMed
  222. Acta Pharmacol Sin. 2017 Jul;38(7):1048-1058 - PubMed
  223. J Control Release. 2017 Oct 10;263:112-119 - PubMed
  224. World J Gastroenterol. 2014 Jan 7;20(1):235-41 - PubMed
  225. J Rural Med. 2017 Nov;12(2):112-119 - PubMed
  226. Eur J Pharm Biopharm. 2007 Aug;67(1):1-8 - PubMed
  227. Hear Res. 2007 Apr;226(1-2):157-67 - PubMed
  228. Fundam Clin Pharmacol. 2020 Feb;34(1):11-19 - PubMed
  229. Cancer Res. 2015 Dec 15;75(24):5248-59 - PubMed
  230. Ophthalmology. 1985 Mar;92(3):402-6 - PubMed
  231. Ann Pharmacother. 1993 Apr;27(4):438-41 - PubMed
  232. Jpn J Clin Oncol. 2006 Mar;36(3):137-41 - PubMed
  233. Cell. 2000 Oct 13;103(2):239-52 - PubMed
  234. Curr Opin Genet Dev. 2002 Feb;12(1):14-21 - PubMed
  235. Biochem Pharmacol. 2001 Oct 15;62(8):1013-23 - PubMed
  236. Intern Med. 1996 Dec;35(12):930-6 - PubMed
  237. Toxicol Pathol. 1986;14(2):247-57 - PubMed
  238. Science. 1992 Oct 23;258(5082):607-14 - PubMed
  239. Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11 - PubMed
  240. Medicina (Kaunas). 2018 Nov 16;54(5): - PubMed
  241. FEBS Lett. 2002 May 8;518(1-3):129-34 - PubMed
  242. Cancer Res. 1991 Jun 1;51(11):2848-53 - PubMed
  243. Oncol Rep. 2012 Aug;28(2):592-600 - PubMed
  244. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6842-7 - PubMed
  245. Gynecol Oncol. 1989 Sep;34(3):323-7 - PubMed
  246. Biochem Pharmacol. 2007 Jan 15;73(2):298-307 - PubMed
  247. Oncogene. 2012 Apr 12;31(15):1869-83 - PubMed
  248. Ann N Y Acad Sci. 2000;926:90-100 - PubMed
  249. Acta Pharm Sin B. 2017 Jan;7(1):3-17 - PubMed
  250. Cancer. 1987 Dec 15;60(12):2869-72 - PubMed
  251. Cancer Chemother Pharmacol. 2010 Sep;66(4):721-8 - PubMed
  252. Life Sci. 2018 Apr 1;198:87-93 - PubMed
  253. J Cancer Res Clin Oncol. 2016 Dec;142(12):2503-2514 - PubMed
  254. EMBO Mol Med. 2013 Nov;5(11):1759-74 - PubMed
  255. Mutat Res. 1978 Jul;51(1):121-32 - PubMed
  256. J Clin Oncol. 1985 Dec;3(12):1683-9 - PubMed
  257. Oncogene. 1997 Jul 3;15(1):45-52 - PubMed
  258. N Engl J Med. 2010 Apr 8;362(14):1273-81 - PubMed
  259. Nature. 2004 May 6;429(6987):92-6 - PubMed
  260. Anticancer Drugs. 2006 Mar;17(3):315-23 - PubMed
  261. Nano Lett. 2018 Jul 11;18(7):4618-4625 - PubMed
  262. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2271-7 - PubMed
  263. BMC Cancer. 2006 Jan 05;6:3 - PubMed
  264. IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 - PubMed
  265. N Engl J Med. 2006 Jan 5;354(1):34-43 - PubMed
  266. Eur J Obstet Gynecol Reprod Biol. 2004 Apr 5;113 Suppl 1:S2-6 - PubMed
  267. J Thorac Oncol. 2013 Jul;8(7):980-4 - PubMed
  268. J Control Release. 2014 May 28;182:90-6 - PubMed
  269. Cytotechnology. 2016 Aug;68(4):1039-48 - PubMed
  270. Colloids Surf B Biointerfaces. 2019 Jun 1;178:199-207 - PubMed
  271. Nat Rev Drug Discov. 2005 Feb;4(2):145-60 - PubMed
  272. Toxicol Appl Pharmacol. 1998 Mar;149(1):24-31 - PubMed
  273. Neurosci Lett. 2010 Nov 5;484(3):210-4 - PubMed
  274. Cell Physiol Biochem. 2015;37(2):816-24 - PubMed
  275. Am J Hum Genet. 2007 Sep;81(3):427-37 - PubMed
  276. Pharmaceuticals (Basel). 2020 Mar 11;13(3): - PubMed
  277. Cancer Res. 2008 Jun 15;68(12):4511-7 - PubMed

Publication Types